Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Celltrion Cuts Deal With Jordan-based Hikma To Sell Its Biosimilars In The Middle East, Africa

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Days after finalizing a deal to sell biosimilar therapeutic antibodies in Israel, Korea's Celltrion has signed a similar agreement with Jordan-based Hikma Pharmaceuticals to market the products across 17 Middle East and Northwestern African countries

You may also be interested in...



Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East

Hikma, one of the fastest growing multinational pharmaceutical companies, reported group revenue Aug. 26 up 11.3 percent year-on-year for the first half of 2010. Diversified among branded, generic and injectables, the Jordanian drug maker attributed the growth to strong generics sales in the U.S

Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East

Hikma, one of the fastest growing multinational pharmaceutical companies, reported group revenue Aug. 26 up 11.3 percent year-on-year for the first half of 2010. Diversified among branded, generic and injectables, the Jordanian drug maker attributed the growth to strong generics sales in the U.S

Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars

SEOUL - Biopharmaceutical firm Celltrion posted a record performance in the most recent quarter due to the company's shift in focus from contract manufacturing to producing biosimilars

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel